Glioblastoma (GBM) is a common and
aggressive brain tumor with
a median survival of 12–15 months. Temozolomide (TMZ) is a
first-line chemotherapeutic agent used in GBM therapy, but the occurrence
of drug resistance limits its antitumor activity. The natural compound
cedrol has remarkable antitumor activity and is derived from Cedrus atlantica. In this study, we investigated the combined
effect of TMZ and cedrol in GBM cells in vitro and in vivo. The TMZ
and cedrol combination treatment resulted in consistently higher suppression
of cell proliferation via regulation of the AKT and MAPK signaling
pathways in GBM cells. The combination treatment induced cell cycle
arrest, cell apoptosis, and DNA damage better than either drug alone.
Furthermore, cedrol reduced the expression of proteins associated
with drug resistance, including O
6-methlyguanine-DNA-methyltransferase
(MGMT), multidrug resistance protein 1 (MDR1), and CD133 in TMZ-treated
GBM cells. In the animal study, the combination treatment significantly
suppressed tumor growth through the induction of cell apoptosis and
decreased TMZ drug resistance. Moreover, cedrol-treated mice exhibited
no significant differences in body weight and improved TMZ-induced
liver damage. These results imply that cedrol may be a potential novel
agent for combination treatment with TMZ for GBM therapy that deserves
further investigation.
The purpose of the study was to elucidate the anti-hepatoma effects and mechanisms of Pogostemon cablin essential oils (PPa extract) in vitro and in vivo. PPa extract exhibited an inhibitory effect on hepatocellular carcinoma (HCC) cells and was less cytotoxic to normal cells, especially normal liver cells, than it was to HCC cells, exerting a good selective index. Additionally, PPa extract inhibited HCC cell growth by blocking the cell cycle at the G0/G1 phase via p53 dependent or independent pathway to down regulated cell cycle regulators. Moreover, PPa extract induced the FAS-FASL-caspase-8 system to activate the extrinsic apoptosis pathway, and it increased the bax/bcl-2 ratio and reduced ΔΨm to activate the intrinsic apoptosis pathway that might be due to lots of reactive oxygen species (ROS) production which was induced by PPa extract. In addition, PPa extract presented to the potential to act synergistically with sorafenib to effectively inhibit HCC cell proliferation through the Akt/mTOR pathway and reduce regrowth of HCC cells. In an animal model, PPa extract suppressed HCC tumor growth and prolonged lifespan by reducing the VEGF/VEGFR axis and inducing tumor cell apoptosis in vivo. Ultimately, PPa extract demonstrated nearly no or low system-wide, physiological, or pathological toxicity in vivo. In conclusion, PPa extract effectively inhibited HCC cell growth through inducing cell cycle arrest and activating apoptosis in vitro and in vivo. Furthermore, PPa extract exhibits less toxicity toward normal cells and organs than it does toward HCC cells, which might lead to fewer side effects in clinical applications. PPa extract may be developed into a clinical drug to suppress tumor growth or functional food to prevent HCC initiation or chemoprotection of HCC recurrence.
Melanoma is a highly metastatic cancer with a low incidence rate, but a high mortality rate. Patchouli alcohol (PA), a tricyclic sesquiterpene, is considered the main active component in Pogostemon cablin Benth, which improves wound healing and has antitumorigenic activity. However, the pharmacological action of PA on anti-melanoma How to cite this article: Chang K-F, Lai H-C, Lee S-C, et al. The effects of patchouli alcohol and combination with cisplatin on proliferation, apoptosis and migration in B16F10 melanoma cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.